A study that intended to test the protective benefits of selenium and vitamin E in prostate cancer instead has found increased risk. Dr. Gerald Chodak discusses the issues.

In addition to issues with incontinence and erectile dysfunction, treatment of prostate cancer is associated with other complications, reports Dr. Gerald Chodak.

Donald Berwick talks with Eric Topol about his decades-long career with the Institute for Healthcare Improvement, his tenure as Director of CMS, and why he's running for governor of Massachusetts.

The paradigm is shifting in the treatment of metastatic, castration-resistant prostate cancer, offering new promise but also new challenges. Dr. Gerald Chodak reviews the issues.

Dr. Gerald Chodak reviews a recent study that could raise undue concern over active surveillance for the right men with prostate cancer.

A major pharmaceutical company plans to stop paying doctors to promote its drugs, which may help curb industry bias but could also impede physician education, says Dr. Gerald Chodak.

A new study suggests that men diagnosed with metastatic prostate cancer might benefit from removing or debulking the primary tumor. Dr. Gerald Chodak explores the validity of the study.

A new study suggests that men who take a phosphodiesterase type 5 inhibitor after radical prostatectomy may not experience a long-term change in penile length. Dr. Gerald Chodak discusses the issues.

Dr. Eric Topol looks at where we stand on bridging the gap between basic science knowledge and clinical practice in the field of cancer genomics.

Some urologists are boosting their bottom lines by referring prostate cancer patients to their own radiation centers. Conflict of interest? Dr. Gerald Chodak discusses the issue.